OBJECTIVES: The IGF axis plays a significant role in normal growth and development and variation in IGFs is associated with health outcomes. Past studies report variation in IGF levels among race/ethnic groups known to differ in disease incidence. This paper reports on race/ethnic variation in serum levels of IGF-I and IGF-BP3 in a nationally representative and ethnically diverse sample of US adults. DESIGN: Serum IGF-I and IGFBP-3 levels from the fasting subsample (n = 6061) of respondents to the US National Health and Nutrition Examination Survey III (NHANES III) were analyzed using an IGF-I ELISA (Diagnostic Systems Laboratory (DSL) 10-5600) and an IGFBP-3 IRMA (DSL 6600). The NHANES is a combined examination and interview survey of a nationally representative sample of US adults. Regression analyses were used to estimate cross-sectional associations between the IGF axis and demographic variables. RESULTS: In unadjusted analyses, serum IGF-I levels were higher in males than in females, and IGFBP-3 levels were higher in females than in males. Both analytes were lower in older adults. Univariate analyses indicate that serum levels of IGF-I are lower in female Non-Hispanic Whites (NHW) (256 [4.9]) and Hispanics (249 [6.6]) than in Non-Hispanic Blacks (NHB) (281 [4.9]). However, in males, IGF levels in NHWs (287 [3.6]) and NHBs (284 [4.3]) are similar and levels in Mexican-Americans are only moderately reduced (265 [3.4]). Notably, NHB's have the highest molar ratio of IGF-I:IGFBP-3 at all ages. After adjustment for age and BMI, gender and race/ethnicity differences persist. CONCLUSIONS: These cross-sectional data support exploration of the IGF axis as an explanation for some race/ethnic differences in cancer incidence.
OBJECTIVES: The IGF axis plays a significant role in normal growth and development and variation in IGFs is associated with health outcomes. Past studies report variation in IGF levels among race/ethnic groups known to differ in disease incidence. This paper reports on race/ethnic variation in serum levels of IGF-I and IGF-BP3 in a nationally representative and ethnically diverse sample of US adults. DESIGN: Serum IGF-I and IGFBP-3 levels from the fasting subsample (n = 6061) of respondents to the US National Health and Nutrition Examination Survey III (NHANES III) were analyzed using an IGF-I ELISA (Diagnostic Systems Laboratory (DSL) 10-5600) and an IGFBP-3 IRMA (DSL 6600). The NHANES is a combined examination and interview survey of a nationally representative sample of US adults. Regression analyses were used to estimate cross-sectional associations between the IGF axis and demographic variables. RESULTS: In unadjusted analyses, serum IGF-I levels were higher in males than in females, and IGFBP-3 levels were higher in females than in males. Both analytes were lower in older adults. Univariate analyses indicate that serum levels of IGF-I are lower in female Non-Hispanic Whites (NHW) (256 [4.9]) and Hispanics (249 [6.6]) than in Non-Hispanic Blacks (NHB) (281 [4.9]). However, in males, IGF levels in NHWs (287 [3.6]) and NHBs (284 [4.3]) are similar and levels in Mexican-Americans are only moderately reduced (265 [3.4]). Notably, NHB's have the highest molar ratio of IGF-I:IGFBP-3 at all ages. After adjustment for age and BMI, gender and race/ethnicity differences persist. CONCLUSIONS: These cross-sectional data support exploration of the IGF axis as an explanation for some race/ethnic differences in cancer incidence.
Authors: D LeRoith; M McGuinness; J Shemer; B Stannard; F Lanau; T N Faria; H Kato; H Werner; M Adamo; C T Roberts Journal: Biol Signals Date: 1992 Jul-Aug
Authors: E A Platz; M N Pollak; E B Rimm; N Majeed; Y Tao; W C Willett; E Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-12 Impact factor: 4.254
Authors: D O Stram; J H Hankin; L R Wilkens; M C Pike; K R Monroe; S Park; B E Henderson; A M Nomura; M E Earle; F S Nagamine; L N Kolonel Journal: Am J Epidemiol Date: 2000-02-15 Impact factor: 4.897
Authors: K Landin-Wilhelmsen; L Wilhelmsen; G Lappas; T Rosén; G Lindstedt; P A Lundberg; B A Bengtsson Journal: Clin Endocrinol (Oxf) Date: 1994-09 Impact factor: 3.478
Authors: Suchi Sood; Erik D Hanson; Matthew J Delmonico; Matthew C Kostek; Brian D Hand; Stephen M Roth; Ben F Hurley Journal: Eur J Appl Physiol Date: 2011-06-11 Impact factor: 3.078
Authors: Stefania I Papatheodorou; Sabine Rohrmann; David S Lopez; Gary Bradwin; Corinne E Joshu; Norma Kanarek; William G Nelson; Nader Rifai; Elizabeth A Platz; Konstantinos K Tsilidis Journal: Cancer Causes Control Date: 2014-01-07 Impact factor: 2.506
Authors: Tanya L Alderete; Courtney E Byrd-Williams; Claudia M Toledo-Corral; David V Conti; Marc J Weigensberg; Michael I Goran Journal: Obesity (Silver Spring) Date: 2010-09-30 Impact factor: 5.002
Authors: Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger Journal: Cancer Prev Res (Phila) Date: 2012-10-03
Authors: Alexandra M V Wennberg; Clinton E Hagen; Mary M Machulda; John H Hollman; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Michelle M Mielke Journal: Neurobiol Aging Date: 2018-02-19 Impact factor: 4.673
Authors: Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields Journal: Breast Cancer Res Treat Date: 2013-03-02 Impact factor: 4.872
Authors: Jay H Fowke; Charles E Matthews; Herbert Yu; Qiuyin Cai; Sarah Cohen; Maciej S Buchowski; Wei Zheng; William J Blot Journal: Endocr Relat Cancer Date: 2010-01-29 Impact factor: 5.678